Monitor for post-trial motions or appeal by plaintiff; the Redx acquisition proxy vote and Nasdaq listing status are the next key catalysts for this micro-cap.
SKYE drugs
SKYE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $1.08entry
- T+1 · 4d ago +0.93%α +1.29% · $1.09
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Skye Bioscience filed a DEFA14A disclosing a unanimous jury verdict in its favor in a former employee's whistleblower retaliation lawsuit, and reminding shareholders of the proposed acquisition of Redx Pharma. The legal win removes a material contingent liability, but the company's $4M market cap and ongoing activist context keep the focus on the Redx deal and Nasdaq listing risk.
Key Financial Metrics
Key Facts
- On November 10, 2026, a jury returned a unanimous verdict in favor of Skye on all claims in the Wendy Cunning whistleblower lawsuit.
- The lawsuit alleged SOX whistleblower violations and California retaliation, seeking unspecified economic and non-economic losses plus attorneys' fees.
- The plaintiff may file post-trial motions and appeal; the company cannot predict the outcome.
- The filing also references the proposed acquisition of Redx Pharma Limited, for which a preliminary proxy statement has been filed.
- Skye's market cap is $4M; activist 5AM Partners VII holds 25.7% and has been selling shares.
- The company faces Nasdaq listing risk, noted in forward-looking statements.
Financial Impact
Lawsuit sought unspecified damages; verdict eliminates potential liability but no financial figure stated.
Risk Factors
- Plaintiff may file post-trial motions or appeal the verdict.
- Redx acquisition may not close or may be delayed; stockholder approval and regulatory conditions remain.
- Nasdaq listing risk is explicitly noted in forward-looking statements.
- Activist 5AM Partners has been reducing its 25.7% stake, signaling reduced conviction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-073123 |
| Document: 0001628280-26-073123-index-headers.html | 0001628280-26-073123 |
| Document: 0001628280-26-073123-index.html | 0001628280-26-073123 |
| Document: 0001628280-26-073123.txt | 0001628280-26-073123 |
Track record
16 reports on SKYE
5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago DEFA14A Neutral 3/10 Viewing Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
- Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
- Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
- Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
- Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
- Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
- Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers